Topic: drug repositioning

BTI will spend the cash on phase 2 trials of a once-failed cancer asset and an old drug repurposed for use in Alzheimer’s and schizophrenia.

The deal gives Roivant, Axovant’s parent company, another part-developed, unloved drug to try to turn into a star.

Qrativ is starting life with $8.3 million, access to its founders’ AI platform and clinical data and a remit to identify treatments for rare diseases.

Tonix Pharmaceuticals has started recruiting military personnel into a phase 3 trial of its drug candidate for combat-related post-traumatic stress disorder (PTSD).

Galapagos has turned to Pharnext to identify low-doses of approved drugs that boost the efficacy of its pipeline prospects.

Amadeus Capital and Jonathan Milner have teamed up to invest in Healx, a startup working with patient advocacy groups to repurpose drugs for rare diseases.

Recursion Pharmaceuticals has raised $12.9 million to scale up its computer-driven approach to drug development.

Astellas has struck its third drug repurposing deal of the past six months. The latest collaboration sees Astellas start working with India's Excelra.